Elisa De Grandis

Elisa De Grandis

Auto-generated profile, based on publicly available information

Elisa De Grandis

Child Neuropsychiatry Unit, IRCCS Istituto Giannina Gaslini, Member of the ERN EpiCARE, Genoa, Italy

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2015 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
EPEleni Panagiotakaki
Eleni Panagiotakaki
EGElisa De Grandis
Elisa De Grandis
MSMichela Stagnaro
Michela Stagnaro
EHErin L. Heinzen
Erin L. Heinzen
CFCarmen Fons
Carmen Fons
AAAlexis Arzimanoglou
Alexis Arzimanoglou
Mutations in the gene ATP1A3 have recently been identified to be prevalent in patients with alternating hemiplegia of childhood (AHC2). Based on a large series of patients with AHC, we set out to identify the spectrum of different mutations within the ATP1A3 gene and further establish any correlation with phenotype. Clinical data from an international cohort of 155 AHC patients (84 females, 71 males; between 3 months and 52 years) were gathered using a specifically formulated questionnaire and analysed relative to the mutational ATP1A3 gene data for each patient. In total, 34 different ATP1A3 mutations were detected in 85 % (132/155) patients, seven of which were novel. In general, mutations were found to cluster into five different regions. The most frequent mutations included: p.Asp801Asn (43 %; 57/132), p.Glu815Lys (16 %; 22/132), and p.Gly947Arg (11 %; 15/132). Of these, p.Glu815Lys was associated with a severe phenotype, with more severe intellectual and motor disability. p.Asp801Asn appeared to confer a milder phenotypic expression, and p.Gly947Arg appeared to correlate with the most favourable prognosis, compared to the other two frequent mutations. Overall, the comparison of the clinical profiles suggested a gradient of severity between the three major mutations with differences in intellectual (p = 0.029) and motor (p = 0.039) disabilities being statistically significant. For patients with epilepsy, age at onset of seizures was earlier for patients with either p.Glu815Lys or p.Gly947Arg mutation, compared to those with p.Asp801Asn mutation (p < 0.001). With regards to the five mutation clusters, some clusters appeared to correlate with certain clinical phenotypes. No statistically significant clinical correlations were found between patients with and without ATP1A3 mutations. Our results, demonstrate a highly variable clinical phenotype in patients with AHC2 that correlates with certain mutations and possibly clusters within the ATP1A3 gene. Our description of the clinical profile of patients with the most frequent mutations and the clinical picture of those with less common mutations confirms the results from previous studies, and further expands the spectrum of genotype-phenotype correlations. Our results may be useful to confirm diagnosis and may influence decisions to ensure appropriate early medical intervention in patients with AHC. They provide a stronger basis for the constitution of more homogeneous groups to be included in clinical trials.

1 August 2009 in Neuropediatrics
Verified
Journal Article
Closed access
PDF file
EGE. De Grandis
E. De Grandis
SPStefano Parodi
Stefano Parodi
MCM. Conte
M. Conte
PAP. Angelini
P. Angelini
FBF. Battaglia
F. Battaglia
EVE. Veneselli
E. Veneselli
Objective: The aim of this study is to describe the long-term neurological, neuropsychological and neuroradiological sequelae and to determine prognostic factors for neurological outcome in children with neuroblastoma-associated opsoclonus-myoclonus-ataxia (OMA) syndrome. Methods: Data on medical history were collected for the study patients. Examinations with grading of neurological signs, neuropsychological tests and brain magnetic resonance imaging with spectroscopy were performed during a follow-up clinic. Results: Fourteen subjects entered the study. All had localized neuroblastoma and they were evaluated after a median of 7.8 years. Patients with a chronic/multiphasic neurological course received steroids combined with intravenous immunoglobulins in the majority of cases. 71% presented neurological sequelae and 62% had a full-scale IQ below the normal range. All patients showed at least some deficit in the neuropsychological functions assessed (language, visual-motor integration, memory, attention and motor ability). Long-term deficits were more frequently detected in patients with an interval of more than 2 months between OMA onset and its diagnosis, even if in most comparisons statistical significance was not reached. Cerebellar atrophy, observed in 36% of patients, was not associated with the neurological outcome. Conclusions: Persisting disability is present in most children with neuroblastoma-associated OMA. However, our results support the role of an early diagnosis of OMA in reducing sequelae and encourage the use of new immunosuppressive therapies.

1 September 2018 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
SGShereen G Ghosh
Shereen G Ghosh
KBKerstin Becker
Kerstin Becker
HHHe Huang
He Huang
TDTracy Dixon-Salazar
Tracy Dixon-Salazar
GCGuoliang Chai
Guoliang Chai
JGJoseph G Gleeson
Joseph G Gleeson

1 May 2011 in Archives of Neurology
Verified
Journal Article
Open access
PDF file
BPBelén Pérez-Dueñas
Belén Pérez-Dueñas
AOAida Ormazábal
Aida Ormazábal
Claudio TomaClaudio Toma
Claudio Toma
BTBarbara Torrico
Barbara Torrico
BCBru Cormand
Bru Cormand
RARafael Artuch
Rafael Artuch
Folate is a B vitamin essential for brain metabolism. It participates in the de novo synthesis of purines and thymidine and, together with cobalamin, represents an important cofactor for homocysteine remethylation and S-adenosylmethionine production by the brain. As with other vitamin deficiency states, folate deficiency may be the consequence of acquired or inherited disorders. Several inborn errors of metabolism can lead to defective folate transport or impaired metabolism, resulting in systemic folate deficiency and, obligatorily, 5-methyltetrahydrofolate (5-MTHF) depletion in the nervous system detectable by assay of cerebrospinal fluid (CSF) levels.1 Cerebral folate deficiency (CFD), however, is characterized by decreased concentrations of 5-MTHF in the CSF in the context of normal systemic folate metabolism.2 The principal mechanistic hypothesis put forth for this condition implies defective transport of folate across the blood-CSF or blood-brain barriers.3,4 Indeed, mutations in the FOLR1 gene (OMIM 136430), encoding the folate receptor α (FRα), can cause brain-specific folate transport deficiency leading to neurodegeneration in early childhood.5 In other patients with CFD, blocking autoantibodies against FRs may also play a pathogenic role.4

1 May 2009 in European Journal of Paediatric Neurology
Verified
Journal Article
Closed access
LRLizzia Raffaghello
Lizzia Raffaghello
MCMassimo Conte
Massimo Conte
EGElisa De Grandis
Elisa De Grandis
VPVito Pistoia
Vito Pistoia

1 June 2017 in Brain and Development
Verified
Journal Article
Closed access
LPLivia Pisciotta
Livia Pisciotta
MGMarcella Gherzi
Marcella Gherzi
MSMichela Stagnaro
Michela Stagnaro
MCMaria Grazia Calevo
Maria Grazia Calevo
MGMelania Giannotta
Melania Giannotta
EGElisa De Grandis
Elisa De Grandis